Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact
New Deal Could Be Worth Over $2.3bn
Executive Summary
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.
You may also be interested in...
Sanofi CEO Takes Not-So-Slow And Steady Approach To COVID-19 Vaccines
Pfizer and BioNTech may be first out of the gate with robust results for a COVID-19 vaccine but amid all the excitement, Paul Hudson has issued a timely reminder that multiple vaccines will be needed to meet the huge demand.
Finance Watch: 14 Biopharma IPOs In One Remarkable Month
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Coronavirus Update: Amid Fears Of Trump Pressure, Fauci Warns Of Rushing Vaccine Authorization
Anthony Fauci says a hasty emergency use authorization for a vaccine would be a mistake - and the FDA commissioner will not be drawn on timelines.
Need a specific report? 1000+ reports available
Buy Reports